Mohs micrographic surgery with melanocytic immunostains (MMS-I) is emerging as an effective treatment option for invasive melanomas, particularly in anatomically constrained areas, due to a low risk of local recurrence and disease-specific mortality, according to study results published in Dermatologic Surgery.
Of Interest
Blood or Marrow Transplant Recipients Face High Risk for Skin Cancer
Survivors of blood or marrow transplant (BMT) face a significant risk of developing cutaneous malignant neoplasms, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma, with a cumulative incidence of 27.4% over 30 years, according to the results of a cohort study.
Dr Buchbinder on the Potential Role for RP1 Plus Nivolumab in Melanoma After PD-1 Progression
Elizabeth Buchbinder, MD, assistant professor, Medicine, Harvard Medical School, senior physician, Medical Oncology, Dana-Farber Cancer Institute, discusses the potential implications of the FDA’s decision to grant breakthrough therapy designation to RP1 (vusolimogene oderparepvec) plus nivolumab (Opdivo) for the treatment of adult patients with advanced melanoma.
Vulvar and Vaginal Melanoma: A Rare but Important Diagnosis
Cutaneous melanoma is a type of skin cancer typically associated with significant ultraviolet radiation exposure. Melanoma arises from melanocytes, cells found within the lower portion of the epidermis that make the pigment melanin.